Clinical Trial: Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT03912831) titled 'Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers' on April 10.

Brief Summary: This study has 2 parts: Phase 1A and Phase 1B. The primary objectives of Phase 1A are to evaluate the safety of KITE-439 and to determine a recommended Phase 1B dose. The primary objective of Phase 1B is to estimate the efficacy of KITE-439 in human leukocyte antigen (HLA)-A*02:01+ adults with relapsed/refractory human papillomavirus (HPV)16+ cancers.

Study Type: Interventional

Condition: Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer

Intervention: * Drug: KITE-439

A single infusion of E7 T-cell...